Ypozane

RSS

osaterone acetate

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the Scientific Discussion (also part of the EPAR).

This EPAR was last updated on 31/08/2021

Authorisation details

Product details
Name
Ypozane
Agency product number
EMEA/V/C/000112
Active substance
osaterone acetate
International non-proprietary name (INN) or common name
osaterone acetate
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QG04CX90
Publication details
Marketing-authorisation holder
Virbac S.A.
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
11/01/2007
Contact address

1ère Avenue 2065 M - L.I.D.
06516 Carros Cedex
France

Product information

27/08/2021 Ypozane - EMEA/V/C/000112 - IAIN/0005

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Urologicals

Therapeutic indication

Treatment of benign prostatic hypertrophy (BPH) in male dogs.

Assessment history

How useful was this page?

Add your rating
Average
5 ratings